Celemics, Inc. Logo

Celemics, Inc.

Develops NGS target enrichment solutions for research and clinical applications.

331920 | KO

Overview

Corporate Details

ISIN(s):
KR7331920009
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 131, A동 19층 및 20층 2004호 외, 금천구

Description

Celemics, Inc. is a biotechnology company that develops and provides Next-Generation Sequencing (NGS) solutions for research and clinical applications. The company specializes in hybridization-based target enrichment technology, offering a comprehensive portfolio of products and services. This includes ready-to-use and customized NGS panels, whole exome sequencing kits, library preparation kits, modular accessories, and bioinformatics analysis services. Celemics' solutions support a wide range of fields, including oncology (somatic cancer, liquid biopsy), inherited diseases, pathogen analysis, pharmacogenomics, and immune repertoire profiling. A key focus is the development of end-to-end customized target enrichment panels, providing support from assay design and optimization to complete bioinformatics analysis. The company's proprietary technologies in probe design and molecular barcoding enable efficient analysis of diverse and challenging sample types.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
반기보고서 (2025.06)
Korean 1.2 MB
2025-05-19 00:00
기업설명회(IR)개최
Korean 6.8 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-27 00:00
정기주주총회결과
Korean 24.8 KB
2025-03-27 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.2 KB
2025-03-19 00:00
감사보고서제출
Korean 25.1 KB
2025-03-19 00:00
사업보고서 (2024.12)
Korean 430.2 KB
2025-03-19 00:00
[기재정정]사업보고서 (2024.12)
Korean 1.5 MB
2025-03-04 00:00
주주총회소집결의
Korean 11.8 KB
2025-03-04 00:00
주주총회소집공고
Korean 158.7 KB
2025-03-04 00:00
주주총회집중일개최사유신고
Korean 4.3 KB
2025-03-04 00:00
의결권대리행사권유참고서류
Korean 159.1 KB
2025-02-19 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB
2024-12-17 00:00
단일판매ㆍ공급계약체결
Korean 9.6 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 1.1 MB

Automate Your Workflow. Get a real-time feed of all Celemics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Celemics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Celemics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.